As Keytruda’s 2028 patent cliff looms, Merck & Co.’s renewed R&D oncology strategy focuses on three strategies. One of those prongs is improving immune responses, a pillar that stars Moderna-shared cancer vaccine mRNA-4157.

A 50% improvement on the time patients could live without disease progression would typically be considered remarkable for a new drug. AstraZeneca’s Tagrisso just delivered an 84% and earned a standing ovation at ASCO 2024.

A new trend has emerged at this year’s American Society of Clinical Oncology conference: the possibility of replacing decades-old chemotherapy with novel approaches. AbbVie wants to "be part of that wave."

Following fellow immunotherapy regimens by Roche and AstraZeneca, Bristol Myers Squibb’s Opdivo and Yervoy want to carve out a piece of the first-line liver cancer market, too.

In the field of anti-CD38 treatment for multiple myeloma, Johnson & Johnson’s Darzalex casts a long shadow. Now, Sanofi hopes a first-in-class win will help its Sarclisa gain an edge.

Armed with two positive phase 3 trial readouts and the hope that at least one will show a significant patient survival benefit, GSK thinks it has the data to convince doctors and the FDA that its once-failed antibody-drug conjugate Blenrep can work in multiple myeloma.

Gilead Sciences is drawing back the curtain on the Trodelvy lung cancer data that previously caused a 10% slide in the company’s stock price. In sharing the detailed results, the company is hanging onto a positive sign in a subgroup of patients who have a high unmet medical need.

As zanidatamab awaits an FDA approval decision, Jazz Pharmaceuticals is sharing long-term phase 2b data in advanced biliary tract cancer for the HER2-targeted bispecific antibody. The data include the first overall survival (OS) findings from the study, with zanidatamab demonstrating a median OS of 15.5 months compared to the typical six to nine months prognosis for patients receiving chemotherapy after first-line therapy.   

Bristol Myers Squibb has divulged the details of Krazati's confirmatory trial. While the study doesn't share the same design problems as Amgen's rival KRAS program, it still leaves open questions about Krazati's regulatory outlook.

When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal. But to Johnson & Johnson’s surprise, a subcutaneous formulation of its lung cancer med Rybrevant proved to work better than the original infusion.

Trial software provider ConcertAI is partnering with Nvidia to develop new clinical simulations that inform future AI products for clinical trials, the company announced May 31 at the American Society of Cancer Oncology’s annual meeting. 

Newly diagnosed chronic myeloid leukemia patients on Scemblix achieved a major molecular response rate of 68% at 48 weeks compared to 49% for older drugs, including Novartis' established Gleevec.